Skip to main content

The Professor Who Had to Spend Half His Life to Make the Drug India Needs

Sujoy Guha has spent 37 years trying to realise Risug, a long-term use reversible male contraceptive – itself an unusual thing. It should have come to be more than a decade ago.


verything is still the same.
Sujoy Kumar Guha, professor emeritus at IIT-Kharagpur, wakes up around 11 am, reads the paper and thinks of what science can offer as solutions to the big problems of the day. In the evenings he runs his PhD students off their feet with constant demands, yet somehow leaves them itching to do something worthy of him. Around midnight, he takes off for a jog around the handsome campus with a leather belt wrapped around his right palm to fend off the stray dogs. He is still the slight, sprightly, soft-spoken man he was. He still answers questions after a few seconds' silence with a lateral anecdote. He still describes most persons as a "very nice man".
Everything is much the same as in 2002, when the then health minister C.P. Thakur had announced the imminent launchof Guha's drug molecule Risug, a reversible male contraceptive. But the clinical trials were then halted on the charge that Risug was toxic. It took five years for the professor to restart the trials. In 2016, Risug is once again almost ready for its launch at the tail end of the phase III clinical trials that have been "99% successful", according to the ICMR. Only, he was 62 then, he is 76 now. And in the past 14 years have been spent in proving what he had already proved successfully.
"We have completed testing on 282 volunteers in five centres across India, and zero side-effects and difficulties have been reported," said Dr R.S. Sharma, head of Reproductive Biology and Maternal Health at the Indian Council of Medical Research (ICMR), in a telephone interview. "I am waiting to reach 300 volunteers and then I will submit Risug for approval to the Drug Controller General of India. It is very unusual, in fact. I have worked on Risug for 25 years and not a single problem has been reported so far."
ᐧ

Comments

Post a Comment

Popular posts from this blog

BE guidelines regarding investigator

BE guidelines recommend investigator should possess appropriate medical qualification, experience for conducting pharmacokinetic studies Can chairperson of EC directly write to sponsor to clarify some of the queries of clinical trial raised in EC meeting? Dr. Sreevatsa Please see an extract from FDA's comment on IRB-sponsor relationship. The interrelationship and interaction between the research sponsor (e.g., drug, biologic and device manufacturers), the clinical investigator and the Institutional Review Board (IRB) may be very complex. The regulations do not prohibit direct sponsor-IRB contacts, although, the sponsor-IRB interaction customarily occurs through the investigator who conducts the clinical study. The clinical investigator generally provides the communication link between the IRB and the sponsor. Such linkage is agreed to by the sponsors and investigators when they sign forms FDA-1571 and FDA-1572, respectively, for drug and biologic studies or a...
Post a Comment
Read more

ICH GCP requires EC members to be independent of investigator and sponsor to avoid conflicts of interest

Can an Ethics Committee member e.g. layman/chairman or anyone in the committee participate in the trial as a subject? Vidya If an Ethics Committee member becomes a trial subject on a trial that he/she was involved in approving then there has been a major conflict of interest. The following situations need to be considered: ● IEC member reviews study without any prior knowledge of the study, votes, and then afterwards is approached by clinical research team to participate. Possibly this is OK but the member should no longer be part of the IEC that reviews that study. This will be difficult in practice, so therefore it is not advisable. ● IEC member already knows about the study and is voting in order to be able to participate. This is clearly not acceptable and made worse if there is additional financial incentive for the study (e.g. volunteer study). ICH GCP requires Ethics Committee members to be independent of the investigator and the sponsor to avoid confl...
Post a Comment
Read more

Combination Vaccine for Kids withdrawn

A vaccine that combines conventional MMR (Measles, Mumps, Rubella) with Chikenpox has been withdrawn in the United States due to a higher rate of seizures in children. In a study children aged 12 to 23 months who received the combined MMR cum Chickenpox vaccine had double the rate of seizures compared to children who got separate vaccine for MMR and chickenpox. This equates to one additional case of convulsion per 2000 vaccinations.
Post a Comment
Read more